- Home
- NVVE vs RDHL Comparison
NVVE vs RDHL Comparison
Compare NVVE & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVE
- RDHL
- Stock Information
- Founded
- NVVE 1996
- RDHL 2009
- Country
- NVVE United States
- RDHL Israel
- Employees
- NVVE N/A
- RDHL N/A
- Industry
- NVVE Oil Refining/Marketing
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- NVVE Energy
- RDHL Health Care
- Exchange
- NVVE Nasdaq
- RDHL Nasdaq
- Market Cap
- NVVE 3.7M
- RDHL 3.8M
- IPO Year
- NVVE N/A
- RDHL N/A
- Fundamental
- Price
- NVVE $1.19
- RDHL $1.99
- Analyst Decision
- NVVE
- RDHL
- Analyst Count
- NVVE 0
- RDHL 0
- Target Price
- NVVE N/A
- RDHL N/A
- AVG Volume (30 Days)
- NVVE 16.6M
- RDHL 214.4K
- Earning Date
- NVVE 05-15-2025
- RDHL 04-10-2025
- Dividend Yield
- NVVE N/A
- RDHL N/A
- EPS Growth
- NVVE N/A
- RDHL N/A
- EPS
- NVVE N/A
- RDHL N/A
- Revenue
- NVVE $5,440,777.00
- RDHL $8,042,999.00
- Revenue This Year
- NVVE $892.33
- RDHL $381.91
- Revenue Next Year
- NVVE N/A
- RDHL N/A
- P/E Ratio
- NVVE N/A
- RDHL N/A
- Revenue Growth
- NVVE N/A
- RDHL 23.17
- 52 Week Low
- NVVE $0.82
- RDHL $1.71
- 52 Week High
- NVVE $9.35
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- NVVE 50.38
- RDHL 51.03
- Support Level
- NVVE $1.19
- RDHL $1.82
- Resistance Level
- NVVE $1.40
- RDHL $1.93
- Average True Range (ATR)
- NVVE 0.20
- RDHL 0.08
- MACD
- NVVE 0.02
- RDHL 0.04
- Stochastic Oscillator
- NVVE 37.56
- RDHL 100.00
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.